1225430-37-4Relevant articles and documents
Novel C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents: Pyridazinylmethylphenyl glucoside congeners
Kim, Min Ju,Lee, Junwon,Kang, Suk Youn,Lee, Sung-Han,Son, Eun-Jung,Jung, Myung Eun,Lee, Suk Ho,Song, Kwang-Seop,Lee, MinWoo,Han, Ho-Kyun,Kim, Jeongmin,Lee, Jinhwa
supporting information; scheme or table, p. 3420 - 3425 (2010/08/07)
Novel C-aryl glucoside SGLT2 inhibitors containing pyridazine motif were designed and synthesized for biological evaluation. Among the compounds tested, pyridazine containing methylthio moiety 22l or thiadiazole ring 22ah showed the best in vitro inhibitory activities in this series (IC50 = 13.4, 11.4 nM, respectively) against SGLT2 to date. Subsequently, compound 22l exhibited reasonable urinary glucose excretion and glucosuria in normal SD rats, thereby demonstrating that this pyridazine series possesses both in vitro SGLT2 inhibition and in vivo efficacy, albeit to a lower degree.